Efficacy of rituximab in autism spectrum disorders associated with genetic deficiency of the folate cycle with signs of antineuronal autoimmunity
Keywords:
immunodiagnostics, immunotherapy, neuropsychiatric disorders, children, diagnostics, therapySynopsis
Advances in genetics, molecular biology, and immunology over the past decades have significantly changed our understanding of the etiology and pathogenesis of autism spectrum disorders (ASD) in children. One of the key advances in this direction is the elucidation of the association of genetic deficiency of the folate cycle (GDFC) with ASD, evidence for which is based on the results of at least 5 meta-analyses of randomized controlled clinical trials and a number of additional controlled trials, the data of which have not yet been properly summarized. It has been established that GDFC leads to pathological biochemical changes in the child's body, which determine the development of encephalopathy with the clinical picture of ASD due to direct (metabolic) and indirect (immune-mediated) mechanisms, and immune-dependent pathways of cerebral damage are currently given a leading role in the pathogenesis of this mental disorder. Among the metabolic disorders induced by GDFC in the child's body, hyperhomocysteinemia, vitamin deficiencies, signs of mitochondrial dysfunction, and impaired nucleotide synthesis and DNA, protein, and lipid methylation processes are distinguished. These pathological biochemical changes lead to the development of persistent oxidative stress, as evidenced by the results of two systematic reviews and meta-analyses of randomized controlled clinical trials on this problem. The result of such disorders are the phenomena of neuro- and immunotoxicity, which underlie the above-mentioned direct and indirect mechanisms of neuronal damage in children with ASD. If we talk about immunotoxicity, it is currently established that in GDFC there is a disturbed development of the child's immune system with the formation of immune dysfunction and dysregulation, which, in turn, cause a phenomenon called a disturbed neuroimmune interface. It is believed that there are at least three main immune-mediated mechanisms of brain damage in GDFC, which can radically affect the development of associated encephalopathy with ASD symptoms. Neurotropic opportunistic and conditionally pathogenic infections, autoimmune reactions to neurons, myelin, glial cells of the cerebral hemispheres and cerebral vessels, systemic and associated intracerebral persistent aseptic inflammation mediated by existing immune dysregulation, constitute the indicated triad of key pathogenetic mechanisms of the development of ASD-forming encephalopathy in GDFC. Suppression or even eradication of these immune-dependent GDFC-induced pathways of CNS damage currently appears to be a promising prospect for effective treatment of ASD in children with GDFC. In particular, it is believed that the suppression of autoimmunity and neurons and myelin can significantly improve the mental functions of sick children. A number of clinical studies have already been conducted in this direction. In particular, clinical case reports and the results of small trials have shown the benefit of using glucocorticosteroids and some other anti-inflammatory agents in children with ASD, the mechanism of action of which is seen precisely in the implementation of anti-inflammatory action and suppression of anti-brain autoimmunity. At least 10 clinical studies have been conducted to test the immunomodulatory agent intravenous normal human immunoglobulin in ASD, which is believed to improve mental functions of patients by suppressing intracerebral inflammation and autoimmune reactions against brain autoantigens. Recently, infliximab, a monoclonal antibody against the tumor necrosis factor alpha molecule, has demonstrated efficacy in suppressing hyperactivity and hyperexcitability in children with ASD associated with GDFC in a controlled clinical trial.
The prospect of developing new, more effective and safe methods of treating immune-mediated encephalopathy in children with ASD is an important task of modern neuroimmunology. Given that autoimmune reactions to CNS autoantigens in ASD are believed to be mainly mediated by autoantibodies rather than cellular autoimmune reactions, the monoclonal antibody to the CD20 molecule of B lymphocytes, rituximab, which has already undergone a number of successful trials in autoimmune diseases with a similar mechanism of development, seems promising for use in such children. Theoretically, by inducing B-cell depletion, rituximab can significantly suppress or even eliminate the production of autoantibodies to brain autoantigens in children with ASD, having a neuroprotective effect and thereby improving the mental status of patients. A dedicated clinical trial testing rituximab in children with ASD associated with GDFC and evidence of anti-brain humoral autoimmunity is needed.
References
Maltsev, D., Yevtushenko, S. (2016). High-Dose Intravenous Immunoglobulin Therapy Efficiency in Children with Autism Spectrum Disorders Associated with Genetic Deficiency of Folate Cycle Enzymes. International Neurological Journal, (2.80), 35–48. https://doi.org/10.22141/2224-0713.2.80.2016.74004
Maltcev, D. V., Natrus, L. V. (2020). The Effectiveness of Infliximab in Autism Spectrum Disorders Associated with Folate Cycle Genetic Deficiency. Psychiatry, Psychotherapy and Clinical Psychology, 3, 583–594. https://doi.org/10.34883/pi.2020.11.3.015
Boris, M., Goldblatt, A., Edelson, S. M. (2005). Improvement in children with autism treated with intravenous gamma globulin. Journal of Nutritional & Environmental Medicine, 15 (4), 169–176. https://doi.org/10.1080/13590840600681827
Bradstreet, J., Singh, V. K., El-Dahr, J. (1999). High dose intravenous immunoglobulin improves symptoms in children with autism. The international symposium on autism. Atnhem.
Cabanlit, M., Wills, S., Goines, P., Ashwood, P., Van de Water, J. (2007). Brain‐Specific Autoantibodies in the Plasma of Subjects with Autistic Spectrum Disorder. Annals of the New York Academy of Sciences, 1107 (1), 92–103. https://doi.org/10.1196/annals.1381.010
Chen, L., Shi, X.-J., Liu, H., Mao, X., Gui, L.-N., Wang, H., Cheng, Y. (2021). Oxidative stress marker aberrations in children with autism spectrum disorder: a systematic review and meta-analysis of 87 studies (N = 9109). Translational Psychiatry, 11 (1). https://doi.org/10.1038/s41398-020-01135-3
Connery, K., Tippett, M., Delhey, L. M., Rose, S., Slattery, J. C., Kahler, S. G. et al. (2018). Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. Translational Psychiatry, 8 (1). https://doi.org/10.1038/s41398-018-0214-7
DelGiudice-Asch, G., Simon, L., Schmeidler, J., Cunningham-Rundles, C., Hollander, E. (1999). Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. Journal of Autism and Developmental Disorders, 29 (2), 157–160. https://doi.org/10.1023/a:1023096728131
Frustaci, A., Neri, M., Cesario, A., Adams, J. B., Domenici, E., Dalla Bernardina, B., Bonassi, S. (2012). Oxidative stress-related biomarkers in autism: Systematic review and meta-analyses. Free Radical Biology and Medicine, 52 (10), 2128–2141. https://doi.org/10.1016/j.freeradbiomed.2012.03.011
Frye, R. E., Sequeira, J. M., Quadros, E. V., James, S. J., Rossignol, D. A. (2012). Cerebral folate receptor autoantibodies in autism spectrum disorder. Molecular Psychiatry, 18 (3), 369–381. https://doi.org/10.1038/mp.2011.175
Guo, B.-Q., Li, H.-B., Ding, S.-B. (2020). Blood homocysteine levels in children with autism spectrum disorder: An updated systematic review and meta-analysis. Psychiatry Research, 291, 113283. https://doi.org/10.1016/j.psychres.2020.113283
Gupta, S. (1999). Treatment of children with autism with intravenous immunoglobulin. Journal of Child Neurology, 14 (3), 203–205. https://doi.org/10.1177/088307389901400314
Gupta, S., Samra, D., Agrawal, S. (2010). Adaptive and Innate Immune Responses in Autism: Rationale for Therapeutic Use of Intravenous Immunoglobulin. Journal of Clinical Immunology, 30 (S1), 90–96. https://doi.org/10.1007/s10875-010-9402-9
Li, Y., Qiu, S., Shi, J., Guo, Y., Li, Z., Cheng, Y., Liu, Y. (2020). Association between MTHFR C677T/A1298C and susceptibility to autism spectrum disorders: a meta-analysis. BMC Pediatrics, 20 (1). https://doi.org/10.1186/s12887-020-02330-3
Lv, M., Zhang, H., Shu, Y., Chen, S., Hu, Y., Zhou, M. (2016). The neonatal levels of TSB, NSE and CK-BB in autism spectrum disorder from Southern China. Translational Neuroscience, 7 (1), 6–11. https://doi.org/10.1515/tnsci-2016-0002
Maltsev, D. V. (2019). Efficiency of a high dose of intravenous immunoglobulin in children with autistic spectrum disorders associated with genetic deficiency of folate cycle enzymes. Journal of Global Pharma Technology, 11 (5), 597–609. Available at: https://www.jgpt.co.in/index.php/jgpt/article/view/2492
Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., Riesgo, R. dos S. (2018). Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy. Neuroimmunomodulation, 25 (5-6), 300–319. https://doi.org/10.1159/000492225
Masi, A., Quintana, D. S., Glozier, N., Lloyd, A. R., Hickie, I. B., Guastella, A. J. (2014). Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Molecular Psychiatry, 20 (4), 440–446. https://doi.org/10.1038/mp.2014.59
Mead, J., Ashwood, P. (2015). Evidence supporting an altered immune response in ASD. Immunology Letters, 163 (1), 49–55. https://doi.org/10.1016/j.imlet.2014.11.006
Melamed, I. R., Heffron, M., Testori, A., Lipe, K. (2018). A pilot study of high‐dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation. Autism Research, 11 (3), 421–433. https://doi.org/10.1002/aur.1906
Shaik Mohammad, N., Sai Shruti, P., Bharathi, V., Krishna Prasad, C., Hussain, T., Alrokayan, S. A. et al. (2016). Clinical utility of folate pathway genetic polymorphisms in the diagnosis of autism spectrum disorders. Psychiatric Genetics, 26 (6), 281–286. https://doi.org/10.1097/ypg.0000000000000152
Nepal, G., Shing, Y. K., Yadav, J. K., Rehrig, J. H., Ojha, R., Huang, D. Y., Gajurel, B. P. (2020). Efficacy and safety of rituximab in autoimmune encephalitis: A meta‐analysis. Acta Neurologica Scandinavica, 142 (5), 449–459. https://doi.org/10.1111/ane.13291
Nicolson, G. L., Gan, R., Nicolson, N. L., Haier, J. (2007). Evidence for Mycoplasma ssp., Chlamydia pneunomiae, and human herpes virus‐6 coinfections in the blood of patients with autistic spectrum disorders. Journal of Neuroscience Research, 85 (5), 1143–1148. https://doi.org/10.1002/jnr.21203
Niederhofer, H., Staffen, W., Mair, A. (2002). Immunoglobulins as an Alternative Strategy of Psychopharmacological Treatment of Children with Autistic Disorder. Neuropsychopharmacology, 28 (5), 1014–1015. https://doi.org/10.1038/sj.npp.1300130
Noriega, D. B., Savelkoul, H. F. J. (2013). Immune dysregulation in autism spectrum disorder. European Journal of Pediatrics, 173 (1), 33–43. https://doi.org/10.1007/s00431-013-2183-4
Plioplys, A. V. (1998). Intravenous Immunoglobulin Treatment of Children With Autism. Journal of Child Neurology, 13 (2), 79–82. https://doi.org/10.1177/088307389801300207
Pu, D., Shen, Y., Wu, J. (2013). Association between MTHFR Gene Polymorphisms and the Risk of Autism Spectrum Disorders: A Meta‐Analysis. Autism Research, 6 (5), 384–392. https://doi.org/10.1002/aur.1300
Rai, V. (2016). Association of methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism with autism: evidence of genetic susceptibility. Metabolic Brain Disease, 31 (4), 727–735. https://doi.org/10.1007/s11011-016-9815-0
Sadeghiyeh, T., Dastgheib, S. A., Mirzaee-Khoramabadi, K., Morovati-Sharifabad, M., Akbarian-Bafghi, M. J., Poursharif, Z. et al. (2019). Association of MTHFR 677C>T and 1298A>C polymorphisms with susceptibility to autism: A systematic review and meta-analysis. Asian Journal of Psychiatry, 46, 54–61. https://doi.org/10.1016/j.ajp.2019.09.016
Saghazadeh, A., Ataeinia, B., Keynejad, K., Abdolalizadeh, A., Hirbod-Mobarakeh, A., Rezaei, N. (2019). A meta-analysis of pro-inflammatory cytokines in autism spectrum disorders: Effects of age, gender, and latitude. Journal of Psychiatric Research, 115, 90–102. https://doi.org/10.1016/j.jpsychires.2019.05.019
Wang, Z., Ding, R., Wang, J. (2020). The Association between Vitamin D Status and Autism Spectrum Disorder (ASD): A Systematic Review and Meta-Analysis. Nutrients, 13 (1), 86. https://doi.org/10.3390/nu13010086
Yektaş, Ç., Alpay, M., Tufan, A. E. (2019). Comparison of serum B12, folate and homocysteine concentrations in children with autism spectrum disorder or attention deficit hyperactivity disorder and healthy controls. Neuropsychiatric Disease and Treatment, 15, 2213–2219. https://doi.org/10.2147/ndt.s212361
Zheng, Z., Zheng, P., Zou, X. (2020). Peripheral Blood S100B Levels in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. Journal of Autism and Developmental Disorders, 51 (8), 2569–2577. https://doi.org/10.1007/s10803-020-04710-1
Downloads
Pages
158-169
Published
May 19, 2025
Categories
Copyright (c) 2025 Dmytro Maltsev
Details about the available publication format: PDF
PDF
ISBN-13 (15)
978-617-8360-21-4
How to Cite
Efficacy of rituximab in autism spectrum disorders associated with genetic deficiency of the folate cycle with signs of antineuronal autoimmunity. (2025). In D. Maltsev, IMMUNODIAGNOSTICS AND IMMUNOTHERAPY OF NEUROPSYCHIATRIC DISORDERS IN CHILDREN (pp. 158–169). Kharkiv: TECHNOLOGY CENTER PC. https://doi.org/10.15587/978-617-8360-21-4.ch12
